Shire Receives FDA “Approvable” Letter On Adult Adderall Product
This article was originally published in The Pink Sheet Daily
Executive Summary
With an adult filing for Adderall replacement Vyvanse set for mid year, the company is weighing its options, Shire told “The Pink Sheet” DAILY.
You may also be interested in...
Shire Targets SHP465 ADHD Resubmission 10 Years After Initial Filing
Shire says it is on track to refile its long-shelved ADHD candidate SHP465 later this year after a Phase III trial in children and adolescents turned out positively.
Shire Finally Gets Resuscitated Adult ADHD Drug Back On Track With FDA
The 16-hour ADHD candidate SHP465 (SPD465) is being aimed at adults, but FDA wants a study in children, which will kick off in August and may allow a launch by the end of 2017, Shire says.
Shire Submits Vyvanse sNDA For Adult ADHD
The company plans to announce data from a Phase III trial in adults in the fourth quarter.